Brief: Newron Reports Compelling Topline Results From All Patients In Study 014
20/03/2023 11:12
March 20 (Reuters) - Newron Pharmaceuticals SpA
NWRN.S :
* NEWRON REPORTS COMPELLING TOPLINE RESULTS FROM ALL
PATIENTS IN
STUDY 014, ITS PHASE II CLINICAL TRIAL EVALUATING EVENAMIDE AS
ADD-ON THERAPY FOR TREATMENT-RESISTANT SCHIZOPHRENIA
Source text for Eikon: ID:nBw6T0QXpa
Further company coverage: NWRN.S
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study